Role of thymidine phosphorylase and orotate phosphoribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinicopathological features of patients with pancreatic cancer

[1]  M. Shimizu,et al.  Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in relation to differentiation of gastric cancer , 2004, International journal of cancer.

[2]  K. Inada,et al.  Immunohistochemical evaluation of thymidylate synthase (TS) and p16INK4a in advanced colorectal cancer: implication of TS expression in 5-FU-based adjuvant chemotherapy. , 2004, Japanese journal of clinical oncology.

[3]  K. Inada,et al.  Immunohistochemical analysis of thymidylate synthase, p16INK4a, cyclin‐dependent kinase 4 and cyclin D1 in colorectal cancers receiving preoperative chemotherapy: Significance of p16INK4a‐mediated cellular arrest as an indicator of chemosensitivity to 5‐fluorouracil , 2004, Pathology international.

[4]  M. Fukushima,et al.  Prognostic significance of orotate phosphoribosyltransferase activity in bladder carcinoma , 2004, Cancer.

[5]  W. Ichikawa,et al.  Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer , 2003, British Journal of Cancer.

[6]  M. Terashima,et al.  Role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in tumour progression and sensitivity to doxifluridine in gastric cancer patients. , 2002, European journal of cancer.

[7]  H. Kitagawa,et al.  Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5'-deoxy-5-fluorouridine as adjuvant chemotherapy. , 2002, Oncology reports.

[8]  M. Kawakami,et al.  Angiogenesis in pancreatic carcinoma , 2001, Cancer.

[9]  K. Ogawa,et al.  Clinicopathological and prognostic significance of thymidine phosphorylase and proliferating cell nuclear antigen in gastric carcinoma. , 2001, Cancer letters.

[10]  H. Shimoji,et al.  Clinical relevance of the concentrations of both pyrimidine nucleoside phosphorylase (PyNPase) and dihydropyrimidine dehydrogenase (DPD) in colorectal cancer. , 2001, Japanese journal of clinical oncology.

[11]  M. Fukumoto,et al.  Gene expression for dihydropyrimidine dehydrogenase and thymidine phosphorylase influences outcome in epithelial ovarian cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  H. Ishitsuka.  Capecitabine: Preclinical Pharmacology Studies , 2000, Investigational New Drugs.

[13]  N. Nagasue,et al.  Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. , 2000, International journal of oncology.

[14]  S. Groshen,et al.  Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  M. Fukushima,et al.  Dihydropyrimidine Dehydrogenase and Messenger RNA Levels in Gastric Cancer: Possible Predictor for Sensitivity to 5‐Fluorouracil , 2000, Japanese journal of cancer research : Gann.

[16]  H. Hamada,et al.  Circumvention of 5‐Fluorouracil Resistance in Human Stomach Cancer Cells by Uracil Phosphoribosyltransferase Gene Transduction , 1999, Japanese journal of cancer research : Gann.

[17]  T. Tsuruo,et al.  Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5-fluorouracil in colorectal cancer. , 1998, Hepato-gastroenterology.

[18]  Y. Shiratori,et al.  Adenovirus-mediated transduction of Escherichia coli uracil phosphoribosyltransferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil. , 1998, Cancer research.

[19]  H. Ishitsuka,et al.  Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. , 1998, Cancer research.

[20]  C. Heid,et al.  A novel method for real time quantitative RT-PCR. , 1996, Genome research.

[21]  M. Fukushima,et al.  Reduced Activity of Anabolizing Enzymes in 5‐Fluorouracil‐resistant Human Stomach Cancer Cells , 1996, Japanese journal of cancer research : Gann.

[22]  O. Dassonville,et al.  Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  S. Akiyama,et al.  Role of thymidine phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factor/thymidine phosphorylase. , 1995, Cancer research.

[24]  R. Diasio,et al.  Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  T. Furukawa,et al.  Angiogenic activity of enzymes , 1994, Nature.

[26]  M. Fukushima,et al.  Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. , 1993, Cancer research.

[27]  T. Furukawa,et al.  Thymidine phosphorylase activity associated with platelet-derived endothelial cell growth factor. , 1993, Journal of biochemistry.

[28]  K. Miyazono,et al.  Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor , 1989, Nature.

[29]  H. Pinedo,et al.  Fluorouracil: biochemistry and pharmacology. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  R. Diasio,et al.  Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. , 1987, Cancer research.

[31]  K. Miyazono,et al.  Purification and properties of an endothelial cell growth factor from human platelets. , 1987, The Journal of biological chemistry.

[32]  H. Ishitsuka,et al.  Enzymatic cleavage of various fluorinated pyrimidine nucleosides to 5-fluorouracil and their antiproliferative activities in human and murine tumor cells. , 1986, Chemical & pharmaceutical bulletin.

[33]  D. Santi,et al.  Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. , 1974, Biochemistry.

[34]  G. Peters,et al.  UFT: mechanism of drug action. , 2000, Oncology.

[35]  F. Cabanillas.  Purine nucleoside analogs in indolent non-Hodgkin's lymphoma. , 2000, Oncology.

[36]  宮寺 和孝.  Role of thymidine phosphorylase activity in the angiogenic effect of platelet-derived endothelial cell growth factor/thymidine phosphorylase , 1999 .